Avalo Therapeutics, Inc. financial data

Symbol
AVTX on Nasdaq
Location
1500 Liberty Ridge Drive, Suite 321, Wayne, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 566 % +701%
Quick Ratio 0.07 % -49%
Debt-to-equity 34.5 %
Return On Equity -48.5 % -135%
Return On Assets -36 % +30%
Operating Margin -15.5K % -993%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.2M shares +1172%
Common Stock, Shares, Outstanding 10.8M shares +948%
Entity Public Float 12.9M USD +169%
Common Stock, Value, Issued 11K USD +1000%
Weighted Average Number of Shares Outstanding, Basic 10.8M shares +947%
Weighted Average Number of Shares Outstanding, Diluted 10.8M shares +41.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 441K USD -77.1%
General and Administrative Expense 20.3M USD +57.6%
Costs and Expenses 60.6M USD +11.1%
Operating Income (Loss) -60.2M USD -11.9%
Nonoperating Income (Expense) 14.1M USD -19.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -46.1M USD -27.3%
Income Tax Expense (Benefit) 124K USD +854%
Net Income (Loss) Attributable to Parent -46.2M USD -27.6%
Earnings Per Share, Basic 125 USD/shares +33.5%
Earnings Per Share, Diluted 131 USD/shares +72.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.3M USD -54.7%
Cash, Cash Equivalents, and Short-term Investments 113M USD
Accounts Receivable, after Allowance for Credit Loss, Current 38K USD
Inventory, Net 0 USD -100%
Assets, Current 115M USD +20.1%
Operating Lease, Right-of-Use Asset 487K USD -59.8%
Goodwill 10.5M USD 0%
Assets 127M USD +16.9%
Accounts Payable, Current 2.37M USD +262%
Employee-related Liabilities, Current 2.14M USD -11.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 9.26M USD -90.4%
Deferred Income Tax Liabilities, Net 293K USD +74.4%
Operating Lease, Liability, Noncurrent 197K USD -83.3%
Other Liabilities, Noncurrent 197K USD -83.3%
Liabilities 22M USD -80.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -34K USD
Retained Earnings (Accumulated Deficit) -404M USD -12.9%
Stockholders' Equity Attributable to Parent 105M USD
Liabilities and Equity 127M USD +16.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.46M USD -52.5%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 10.8M shares +948%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.46M USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.5M USD -54.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 65.7M USD +15.4%
Deferred Tax Assets, Gross 65.4M USD +15.2%
Operating Lease, Liability 679K USD -60.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20.8M USD -121%
Lessee, Operating Lease, Liability, to be Paid 735K USD -64.5%
Operating Lease, Liability, Current 482K USD -12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 63K USD -88.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 392K USD -29.1%
Deferred Income Tax Expense (Benefit) 8K USD +14.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 56K USD -83.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 42.7M USD +14.5%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Additional Paid in Capital 509M USD +47.7%
Amortization of Intangible Assets 0 USD -100%
Depreciation, Depletion and Amortization 135K USD +297%
Share-based Payment Arrangement, Expense 10.7M USD +279%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%